Arash Mahajerin
Pediatric Hematology-Oncology · Orange, CANPI 1033315247
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by AstraZeneca at 38.0% of the total. Reporting peaked in 2019 at $99,301 and has fallen 99.9% since, to $109 in 2025. Among pediatric hematology-oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $705.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$94K
- Genentech USA, Inc.$81K
- Spark Therapeutics, Inc.$51K
- Kedrion Biopharma, Inc.$6K
- Novo Nordisk$5K
- F. Hoffmann-la Roche AG$4K
- plus $7K from 13 others
Across 11 payments — averaging $2543.54 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$14K
- F. Hoffmann-la Roche AG$14K
What the payments were for
- Consulting fees$69,82428%
- Speaking & faculty fees$132,49453%
- Grants$4,7862%
- Travel & lodging$29,95812%
- Food & beverage$11,8745%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 149 | $94,487 |
| Genentech USA, Inc. | 88 | $81,114 |
| Spark Therapeutics, Inc. | 69 | $51,112 |
| Kedrion Biopharma, Inc. | 2 | $6,000 |
| Novo Nordisk | 3 | $4,786 |
| F. Hoffmann-la Roche AG | 3 | $4,044 |
| Sanofi | 4 | $2,683 |
| Genentech, Inc. | 9 | $1,470 |
| Kedrion Biopharma Inc. | 1 | $1,200 |
| Grifols Shared Services North America, Inc. | 11 | $1,095 |
| Apellis Pharmaceuticals, Inc. | 4 | $300 |
| Tersera Therapeutics LLC | 1 | $257 |
| Amneal Pharmaceuticals LLC | 1 | $204 |
| Grifols USA, LLC | 1 | $62 |
| Amgen(2 entities) | 2 | $41 |
| Novartis | 2 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Chiesi USA, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HEMLIBRA$83,429
- ULTOMIRIS$23,252
- Albuked$7,200
- KOATE$7,200
- GAMMAKED$7,200
- KEDRAB$7,200
- RhoGAM Ultra-Filtered PLUS$7,200
- SOLIRIS$3,596
- Thrombate III$677
- Empaveli$123
How this compares
$248,936 in reported general payments places this provider in the 95th percentile of 307 pediatric hematology-oncology providers in California.
See all pediatric hematology-oncology providers in California →
Other pediatric hematology-oncology in Orange
- Vanessa Salinas-LunaOrange$344K
- Amit SoniOrange$70K
- Esteban GomezOrange$56K
- Diane NugentOrange$55K
- van HuynhOrange$37K
- Mariko SatoOrange$21K
- Philip PizzoPalo Alto$2.6M
- Vinod BalasaMadera$508K
- Akshat JainRedlands$447K
- Noah FedermanLos Angeles$399K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.